Gilteritinib (ASP2215)

Catalog No.S7754

For research use only.

Gilteritinib (ASP2215) is a small-molecule FLT3/AXL inhibitor with IC50 values of 0.29 nM and 0.73 nM for FLT3 and AXL, respectively. It inhibits FLT3 at an IC50 value that was approximately 800-fold more potent than the concentration required to inhibit c-KIT (230 nM).

Gilteritinib (ASP2215) Chemical Structure

CAS No. 1254053-43-4

Selleck's Gilteritinib (ASP2215) has been cited by 22 publications

Purity & Quality Control

Choose Selective FLT3 Inhibitors

Other FLT3 Products

Biological Activity

Description Gilteritinib (ASP2215) is a small-molecule FLT3/AXL inhibitor with IC50 values of 0.29 nM and 0.73 nM for FLT3 and AXL, respectively. It inhibits FLT3 at an IC50 value that was approximately 800-fold more potent than the concentration required to inhibit c-KIT (230 nM).
Targets
FLT3 [1]
(Cell-free assay)
Axl [1]
(Cell-free assay)
0.29 nM 0.73 nM
In vitro

Gilteritinib demonstrates potent inhibitory activity against the internal tandem duplication (FLT3-ITD) and FLT3-D835Y point mutations in cellular assays using MV4-11 and MOLM-13 cells as well as Ba/F3 cells expressing mutated FLT3. Gilteritinib decreases the phosphorylation levels of FLT3 and its downstream targets in both cellular and animal models. Gilteritinib inhibits the activity of eight of the 78 tested kinases by over 50% at concentrations of either 1 nM (FLT3, LTK, ALK, and AXL) or 5 nM (TRKA, ROS, RET, and MER)[1]. Gilteritinib treatment for 48h results in an induction of apoptosis in MV4-11 cells as determined by an increase in annexin V-positive cells. Gilteritinib also decreases the expression of anti-apoptotic proteins such as MCL-1, BCL2L10, and survivin, which are reported to be important in chemotherapy sensitivity, following 24h treatment[2].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV4-11 cells NWDZZXF[S2WubDDjfYNt\SCjc4PhfS=> MnjXNUwhOyxiMUCsJIFv\CB|MDDuUS=> MY[yOEBp M3[yb3Rp\SCvZXHuJJBzd3CxcoTpc44hd2ZiTW[0MVEyKGOnbHzzJIlvKEdzIIDoZZNmKHencnWgd4lodmmoaXPhcpRtgSCrbnPy[YF{\WRiYYSg[4ltfGW{aYTpcoljKGOxbnPlcpRz[XSrb37zJI9nKDNiKE[5MlAmQyCSPECuNFEqKGGwZDCxNEBvVSBqN{CuO{U8KFB:MD6wNFEqNg>? M13ydVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzME[5NFE2Lz5|MUC2PVAyPTxxYU6=
MOLM-13 cells MXTBdI9xfG:|aYOgZZN{[Xl? NX\ZUJROOSxiMzygNVAtKDNyLDDhcoQhOTByIH7N NH3wW3k1QCCq MlS5d4lodmmoaXPhcpQhcW6lcnXhd4V{KGmwIITo[UBx\XKlZX70ZYdmKG:oIHHucoV5cW5iVj3wc5NqfGm4ZTDj[YxteyCjdDDjc45k\W62cnH0bY9veyCxZjCzNEBvVSBqM{KuNEUqKGGwZDCxNFAhdk1iKEWyMlQmMSC4ZYLzeZMh[2:wdILvcEApPC5zJTm= MmHoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFyNkmwNVUoRjNzME[5NFE2RC:jPh?=
32D/TKD cells MoP2SpVv[3Srb36gZZN{[Xl? NVjo[VlGPTBibl5CpC=> Mn\DOkBp Mmr4TY5pcWKrdH;uJI9nKHSqZTDwbI9{eGixconsZZRqd25ib3[gRYt1KG:wIGSzNFg> MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTVyN{[2NEc,Ojl3MEe2OlA9N2F-
TF-1 cells NFzOTWNHfW6ldHnvckBie3OjeR?= MV:wMEAzOCxiOECsJFIxOCCjbnSgOVAxKG6P MVKxJIg> NXnqW4FX\2mudHXybZRqdmmkIHjhd{BidiCLQ{WwJIFo[Wmwc4Sge4lt\C22eYDlJIMuU2m2IH;mJFExOiCwTR?= Ml;lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MEi4PFEoRjJ5OUC4PFgyRC:jPh?=
BA/F3 MXnGeY5kfGmxbjDhd5NigQ>? MXrJcohq[mm2aX;uJGF{e2G7OjDBJJJm[2:vYnnuZY51KHKndILveolzfXNid3HzJINz\WG2ZXSg[pJwdSCneIDy[ZN{cW:wIIDsZZNucWRiRlzBS{1GVUx2LVHMT5YyN3CPWD3pdoV{S0R6IHnuJJdpcWOqIHPEUmEh\m:{IFXNUGEuSUyNIH\1d4lwdiCycn;0[YlvKHZzIIfhd{BqdnSnZ4LheIVlNCCjbnSgbY5r\WO2ZXSgbY51dyCvb4Xz[UBtgW2yaH;p[EBk\WyuIHzpcoUhSkFxRkOgZ4VtdHNwIGXzbY5oKGFibXHncoV1cWNiYnXh[EBz\WGpZX70JIYtKEmFNUCgQUAxNjByMUWg{txONg>? MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzN|AyPjJ{Lze+R4hGVUKOPD;hQi=>
BA/F3 M1zWUGZ2dmO2aX;uJIF{e2G7 NXPocmpvUW6qaXLpeIlwdiCDc4PhfVohSSC{ZXPvcYJqdmGwdDDy[ZRzd3[rcoXzJJdieyClcnXheIVlKG[{b32g[ZhxemW|c3nvckBxdGG|bXnkJGZNSUdvRV3MOE1CVEu4MT;wUXgucXKnc1PEPEBqdiC5aHnjbEBkTE6DIH\vdkBGVUyDLVHMT{BnfXOrb36gdJJwfGWrbjD2NUB4[XNiaX70[Ydz[XSnZDygZY5lKGmwanXjeIVlKGmwdH:gcY92e2VibIntdIhwcWRiY3XscEBtcW6nIFLBM2Y{KGOnbHzzMkBWe2mwZzDhJI1i\26ndHnjJIJm[WRicnXh[4VvfCCoLDDJR|UxKD1iMD6wNFE2KM7:TT6= M{jtSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM{ODF4MkKvK|5EcEWPQly8M4E,
Vero NGHiN41CdnSrdnnyZYwh[XO|YYm= MUWyOEBpeg>? NIjkU5dCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBUSVKVLVPvWk0zKCi4aYLhcEB1cXSncjmgcYVie3W{ZXSgZpkheGyjcYXlJIF{e2G7IHnuJHZmem9iY3XscJMh[XRiTV;JJFAvODF{NTDh[pRmeiB{NDDodkwhUUN3MDC9JFYvPzZizszNMi=> Mly4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|MxOTZ{Mj:nQmNpTU2ETEyvZV4>
Vero NY\USIFPS2WubDD2bYFjcWyrdImgZZN{[Xl? NEfaZmg4OiCqch?= M4e0R2NmdGxidnnhZoltcXS7IH3lZZN2emWmIHL5JGNmdGyWaYTldk1IdG9iYYPzZZkhcW5iVnXyc{Bk\WyuczDheEBOV0liMD6wOUBi\nSncjC3NohzNCCFQ{WwJF0hOzdwMU[g{txONg>? NID0PFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OzBzNkKyM{c,S2iHTVLMQE9iRg>?
Assay
Methods Test Index PMID
Western blot p-STAT5 / STAT5 / p-AKT / AKT / p-ERK / ERK ; p-c-kit / c-kit ; p-FLT3(Y591) / FLT3 28516360 27908881 30344940
In vivo In vivo, gilteritinib is distributed at high levels in xenografted tumors after oral administration. The decreased FLT3 activity and high intratumor distribution of gilteritinib translates to tumor regression and improved survival in xenograft and intra-bone marrow transplantation models of FLT3-driven AML. This antitumor activity is associated with a durable inhibition of phospho-FLT3 and phospho-STAT5. Furthermore, treatment with gilteritinib decreases the leukemic burden and prolongs survival in a mouse IBMT model. No overt toxicity is seen in mouse models treated with gilteritinib[1].

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: MV4-11 cells
  • Concentrations: 0.1 nM, 1 nM, and 10 nM
  • Incubation Time: 2 h
  • Method:

    MV4-11 cells are treated with DMSO or increasing concentrations of gilteritinib for 2 hours. Immunoprecipitation and immunoblot for phosphorylated FLT3 and total FLT3 are performed.

Animal Research:

[1]

  • Animal Models: MV4-11 xenografted mice (Nude mice)
  • Dosages: 1 mg/kg, 6 mg/kg, and 10 mg/kg
  • Administration: oral

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 552.71
Formula

C29H44N8O3

CAS No. 1254053-43-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04699877 Recruiting Drug: Gilteritinib Renal Impaired|Gilteritinib|Normal Renal Function|Pharmacokinetics of ASP2215 Astellas Pharma Global Development Inc.|Astellas Pharma Inc January 28 2021 Phase 1
NCT04140487 Recruiting Drug: Azacitidine|Drug: Gilteritinib|Drug: Venetoclax Recurrent Acute Myeloid Leukemia|Recurrent Chronic Myelomonocytic Leukemia|Recurrent Myelodysplastic/Myeloproliferative Neoplasm|Refractory Acute Myeloid Leukemia|Refractory Chronic Myelomonocytic Leukemia|Refractory Myelodysplastic/Myeloproliferative Neoplasm M.D. Anderson Cancer Center December 17 2019 Phase 1|Phase 2
NCT03730012 Completed Drug: gilteritinib|Drug: atezolizumab Acute Myeloid Leukemia (AML)|Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation Astellas Pharma Global Development Inc.|Astellas Pharma Inc June 19 2019 Phase 1|Phase 2
NCT03964038 Completed Drug: gilteritinib|Drug: gilteritinib mini tablet Healthy Volunteer Astellas Pharma Global Development Inc.|Astellas Pharma Inc May 21 2019 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Gilteritinib (ASP2215) | Gilteritinib (ASP2215) supplier | purchase Gilteritinib (ASP2215) | Gilteritinib (ASP2215) cost | Gilteritinib (ASP2215) manufacturer | order Gilteritinib (ASP2215) | Gilteritinib (ASP2215) distributor